Targeted Overexpression of NDRG2 Using Survivin Promoter Reduces Viability and Invasiveness of A549 Cell Line

Overview

Journal Avicenna J Med Biotechnol

Specialty Biomedical Engineering

Date 2023 Apr 10

PMID 37034887

Authors

Maryam Fanian

Gholamreza Rafiei

Marzieh Alizadeh Zarei

Mohammad Ali Takhshid

Affiliations

Soon will be listed here.

Abstract

Background: Anti-tumor effects of N-myc Downstream Regulated Gene2 (NDRG2) have been demonstrated in many tumors. In the present study, NDRG2 was specifically overexpressed in lung cancer cell line using Survivin Promoter (Sur-P). Then, the effects of NDRG2 overexpression on viability, apoptosis, migration, and invasion of A549 cells were evaluated.

Methods: Recombinant pAdenoVator-Sur-P-NDRG2-IRES-GFP plasmid harboring gene under transcriptional control of Sur-P and mock plasmid were constructed. A549 lung tumor cells and LX-2 cells (non-tumor cell line) were transfected with pAdenoVator-Sur-P-NDRG2-IRES-GFP, pAdenoVator-CMV-NDRG2-IRES-GFP, or mock plasmids. Tumor specificity of Sur-P was evaluated using fluorescent microscopy for GFP expression. The effects of overexpression on cell viability, apoptosis, and migration of A549 cells were measured using MTT, annexinV/7-AAD flow cytometry, and transwell migration assay, respectively. and matrix metalloproteinase-2 () expression were measured using real time-PCR.

Results: pAdenoVator-Sur-P-NDRG2-IRES-GFP transfection resulted in a huge GFP expression in A549 cells, but not in LX-2 cells. The results of real time-PCR analysis also showed that pAdenoVator-Sur-P-NDRG2-IRES-GFP transfection led to an abundant expression in A549 cells. overexpression decreased A549 cell viability through increasing cell apoptosis. In addition, migration, invasion, and expression decreased following overexpression in A549 cells.

Conclusion: The findings indicate that the targeted overexpression of using Sur-P can reduce the viability and invasiveness of A549 cells, suggesting possible benefits of this approach in lung cancer therapy.

References

Kang F, Wang Y, Luo Y, Zhang Y . NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis. J Ovarian Res. 2020; 13(1):48. PMC: 7189606. DOI: 10.1186/s13048-020-00649-0. View

Darayee M, Geramizadeh B, Tabei S, Rezvani A, Soleimanian S, Rahimi A . Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy. Asian Pac J Cancer Prev. 2022; 23(6):1993-2000. PMC: 9587823. DOI: 10.31557/APJCP.2022.23.6.1993. View

Li D, Hu C, Li H . Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep. 2018; 8(5):399-406. PMC: 5920485. DOI: 10.3892/br.2018.1077. View

Zhu Z, Makhija S, Lu B, Wang M, Kaliberova L, Liu B . Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 2004; 11(4):256-62. DOI: 10.1038/sj.cgt.7700679. View

Farokhinejad F, Behbahani A, Dehbidi G, Takhshid M . Expression and purification of TAT-NDRG2 recombinant protein and evaluation of its anti-proliferative effect on LNCaP cell line. Protein Expr Purif. 2017; 138:25-33. DOI: 10.1016/j.pep.2017.07.004. View

Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T . Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun. 2014; 5:3393. PMC: 3948061. DOI: 10.1038/ncomms4393. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Mohammadi V, Behbahani A, Rafiee G, Hosseini S, Alizadeh Zarei M, Okhovat M . The effects of specific expression of apoptin under the control of PSES and PSA promoter on cell death and apoptosis of LNCaP cells. Iran J Basic Med Sci. 2017; 20(12):1354-1359. PMC: 5722996. DOI: 10.22038/IJBMS.2017.9598. View

Min H, Lee H . Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharm Res. 2021; 44(2):146-164. DOI: 10.1007/s12272-021-01312-y. View

10.

Bao R, Connolly D, Murphy M, Green J, Weinstein J, Pisarcik D . Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 2002; 94(7):522-8. DOI: 10.1093/jnci/94.7.522. View

11.

Alizadeh Zarei M, Rafiei Dehbidi G, Takhshid M . Combination of NDRG2 overexpression, X-ray radiation and docetaxel enhances apoptosis and inhibits invasiveness properties of LNCaP cells. Urol Oncol. 2020; 38(11):849.e1-849.e9. DOI: 10.1016/j.urolonc.2020.06.017. View

12.

Tantai J, Pan X, Hu D . RNF4-mediated SUMOylation is essential for NDRG2 suppression of lung adenocarcinoma. Oncotarget. 2016; 7(18):26837-43. PMC: 5042018. DOI: 10.18632/oncotarget.8663. View

13.

Merchant N, Nagaraju G, Rajitha B, Lammata S, Jella K, Buchwald Z . Matrix metalloproteinases: their functional role in lung cancer. Carcinogenesis. 2017; 38(8):766-780. DOI: 10.1093/carcin/bgx063. View

14.

Chen X, Lei L, Hong L, Ling Z . Potential role of NDRG2 in reprogramming cancer metabolism and epithelial-to-mesenchymal transition. Histol Histopathol. 2017; 33(7):655-663. DOI: 10.14670/HH-11-957. View

15.

Ma J, Kong L, Liao C, Jiang X, Wang Y, Bao T . Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion. Med Oncol. 2012; 29(5):3306-13. DOI: 10.1007/s12032-012-0265-1. View

16.

Golestan MSc A, Mojtahedi PhD Z, Ghalamfarsa PhD G, Hamidinia MSc M, Takhshid PhD M . The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line. Iran J Med Sci. 2015; 40(5):430-9. PMC: 4567603. View

17.

Alekseenko I, Pleshkan V, Sass A, Filyukova O, Snezhkov E, Sverdlov E . A Universal Tumor-Specific Promoter for Cancer Gene Therapy. Dokl Biochem Biophys. 2018; 480(1):158-161. DOI: 10.1134/S1607672918030092. View

18.

Olaussen K, Postel-Vinay S . Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016; 27(11):2004-2016. DOI: 10.1093/annonc/mdw321. View

19.

Hashemi Z, Moghadam M, Farokhimanesh S, Rajabibazl M, Sadroddiny E . Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics. Iran J Basic Med Sci. 2018; 21(4):427-433. PMC: 5960762. DOI: 10.22038/IJBMS.2018.26614.6522. View

20.

Yang L, Cao Z, Li F, Post D, Van Meir E, Zhong H . Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 2004; 11(15):1215-23. PMC: 3163156. DOI: 10.1038/sj.gt.3302280. View